In this low interest rate environment, investors have turned to high-yielding blue-chips as a source of retirement income. This five-part series will outline what I believe to be the top five dividend aristocrat stocks, most suitable for a retiree’s portfolio. In my previous articles on… Read More
Melvin Pasternak, Ph.D., is an experienced market technician. He designed a course for TD Waterhouse titled "Winning in the Stock Market," which combined intensive technical and fundamental analysis to uncover how to profitably beat the market. Dr. Pasternak was a professor at the Mount Royal University in Calgary, Alberta, for more than 25 years. In 2006, after retiring, he published his book on candlestick charting, 21 Candlesticks Every Trader Should Know. Due to his trading expertise, he has been interviewed several times by CBC Radio-Canada and the Calgary Herald.
Analyst Articles
Low prices for this commodity are leading to new and innovative ways to use it. Read More
What on Earth is Steven A. Cohen thinking? He’s authorized traders at his investment firm, SAC Capital, to quickly build a large position in Accretive Health (NYSE: AH). Roughly a week ago, SAC announced that it had already bought so many shares that it… Read More
The second quarter of 2012 has been a bummer so far, especially when you think back to what was a great first quarter in which the S&P 500 rose more than 12%. But I’m not discouraged. While the recovery may be proceeding at an excruciatingly slow pace, I still think… Read More
To Europe’s leaders and Greek voters, here’s a modest request: Will you please flip over all the cards and make the bold moves that markets are increasingly expecting? At this point, providing further bailout funds for Greece is simply foolish. No amount of money can turn this… Read More
Uber-investor Warren Buffett and I are quite different. Whereas Buffett typically looks for undervalued companies and buys them for the long haul, I usually like to buy stocks that are on a long-term uptrend that have a temporary pullback. And the quicker I can make a decent… Read More
Generic prescription drugs are the bane of big pharmaceutical companies and investors alike. As patents for name brand drugs expire, generics eat into revenue, shrink earnings, and depress stock prices of the Big Pharma players. But the smart investor knows that… Read More
In the past, I’ve told you where to find 57% of America’s best income stocks. For those who didn’t read that article, my research team found that 12 of the 21 best-performing American income stocks of the past decade came from a single sector — energy. (You… Read More
Over the past few years, I’ve been imploring investors to boost their exposure to the more dynamic economies and regions of the world. Simply put, Latin America, Asia and even Africa are poised to grow at a stronger pace in the next few decades than the United States and Europe. Read More
Every two weeks, we get a chance to look at fresh data on how heavily stocks are being shorted. It helps to see what short-sellers are focusing on — especially if you own one of the stocks being targeted. You’ll often see short positions in a particular… Read More